Confronto
Dulaglutide vs. Tirzepatide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
923950-08-7
2023788-19-2
Peso molecolare
59670 g/mol
4813 g/mol
Emivita
110 h
116 h
Sequenza
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMeccanismo d'azione
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
4
di cui sull'uomo
5
4
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Dulaglutide and Tirzepatide?
- Dulaglutide is classified as "Metabolico", while Tirzepatide is classified as "Metabolico". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Tirzepatide?
- The highest available evidence level is "RCT sull'uomo" for Dulaglutide and "RCT sull'uomo" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Tirzepatide in Germany and the United States?
- Germania: Dulaglutide — Su prescrizione, Tirzepatide — Su prescrizione. Stati Uniti: Dulaglutide — Su prescrizione, Tirzepatide — Su prescrizione. These are factual summaries with source and review date on the individual pages.